Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BOSTON-4: A Phase IIa Multi-Center, Randomized, Single-Blind Safety and Tolerability Study of inhaled Liposomal Cyclosporine A in Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation

Next Previous
Trial Profile

BOSTON-4: A Phase IIa Multi-Center, Randomized, Single-Blind Safety and Tolerability Study of inhaled Liposomal Cyclosporine A in Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Bronchiolitis obliterans
  • Focus Adverse reactions
  • Acronyms BOSTON-4
  • Sponsors Breath Therapeutics; Zambon SpA

Most Recent Events

  • 08 Sep 2023 Status changed from active, no longer recruiting to discontinued. Due to the low number of patients recruited and the slow enrollment pace of patients, on 18March 2022, the sponsor decided to terminate the BOSTON-4 safety and tolerability trial ahead of time.
  • 07 Jul 2022 This trial has been completed in France, according to European Clinical Trials Database record.
  • 04 Jul 2022 This trial has been completed in Germany (Global end date: 16 Jun 2022).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top